AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.

- 1. (Currently Amended) A method for the therapeutic treatment of a <u>carcinoma</u> eancer in a mammal wherein (i) the mammal comprises a mutated fibroblast growth factor receptor-4 (FGFR-4) protein, and (ii) the mutated FGFR-4 <u>protein</u> comprises <u>the amino acid</u> sequence of SEQ ID NO: 9 except that glycine at position 388 of SEQ ID NO: 9 has been <u>substituted with arginine</u>, at least one point mutation in the transmembrane domain of FGFR-4 that substitutes a hydrophilic amino acid for a hydrophobic amino acid, which method comprises administering to the mammal an effective amount of at least one inhibitor of the mutated FGFR-4, wherein the <u>carcinoma eancer</u> in the mammal is treated.
 - 2. (Canceled)
- 3. (Currently Amended) The method of claim 1, wherein said <u>carcinoma eancer</u> is breast cancer, squamous cell carcinoma, glioblastoma, neuroblastoma, or uterine cancer.
- 4. (Original) The method of claim 1, wherein said inhibitor is a kinase-inactive receptor.
 - 5.-12. (Canceled)
- 13. (Currently Amended) The method of claim 1, wherein the <u>mutated FGFR-4</u> protein is encoded by a FGFR-4 gene comprising mutation is a germ line mutation.
 - 14.-29. (Canceled)